Business
Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020
-- People Living With HIV Switching to Biktarvy from Boosted PI-Based Regimens Achieved Sustained Viral Suppression up to 156 Weeks -- -- Ongoing Switch
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n-- People Living With HIV Switching to Biktarvy from Boosted PI-Based Regimens Achieved Sustained Viral Suppression up to 156 Weeks --\n\n-- Ongoing Switch Study in Population Aged 65 Years and Older Shows Biktarvy Sustains Viral Suppression Through 72 weeks --\n\n-- Clinical and Patient Reported Outcomes in People Living With HIV on Biktarvy Treatment in the international BICSTaR Study Demonstrated Consistent Therapeutic Effectiveness and Long-term Safety Profile in Real-World Practice Settings --\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GLD) today announced long-term study results, which showed that people living with HIV who switched to the once-daily, single tablet regimen, Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) from a boosted protease inhibitor-based regimen consisting of atazanavir (ATV) or darunavir (DRV) plus either emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) or abacavir (ABC)/lamivudine (3TC) maintained virologic suppression (defined as HIV-1 RNA","length":1401,"tagName":"div"}]